Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTJQFBG)

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

1 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ciclopirox	DMN5T2A	Cutaneous candidiasis	1F23.14	Approved	[1]
------------------------------------------------------------------------------------

6 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AKB-6548	DM2EJM3	Anaemia	3A90	Phase 3	[2]
BAY 853934	DM407I6	Anaemia	3A90	Phase 3	[3]
JTZ-951	DM8FSPV	Anaemia	3A90	Phase 3	[4]
FG-2216	DM7RYL4	Kidney disease	GC2Z	Phase 2	[5]
DS-1093	DM42KZW	Anemia	3A00-3A9Z	Phase 1	[6]
ZYAN1	DM796RI	Anaemia	3A90	Phase 1	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Clinical Trial Drug(s)

1 Preclinical Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
JNJ-42905343	DMCNBHY	Anaemia	3A90	Preclinical	[8]
------------------------------------------------------------------------------------

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This DTT

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Shwachman-Diamond syndrome	3B64	Bone marrow	7.70E-01	4.40E-03	0.02
------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
2	DOI: 10.1038/nrd4422
3	Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia. ChemMedChem. 2018 May 23;13(10):988-1003.
4	DOI: 10.1038/nrneph.2015.82
5	Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD
6	Company report (Daiichisankyo)
7	Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Drug Res (Stuttg). 2016 Feb;66(2):107-12.
8	Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats. Br J Pharmacol. 2015 Aug;172(16):4078-88.